CurrentCignaPolicy N/A

Romvimza (vimseltinib) prior authorization for tenosynovial giant cell tumor

Defines prior authorization requirements and medical necessity criteria for Romvimza (vimseltinib capsules) for Cigna-administered health benefit plans, focusing on treatment of tenosynovial giant cell tumor (TGCT) in adults.

Policy Summary

PayerCigna

PolicyRomvimza (vimseltinib) prior authorization for tenosynovial giant cell tumor

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 19, 2025

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and document age (≥18), TGCT diagnosis, and that the tumor is not amenable to improvement with surgery; approvals are for 1 year when criteria met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearapproval duration

Adults ≥18minimum age

TGCT onlycovered indication

Excludedother uses

NCCN preferredguideline

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy (FDA‑approved TGCT)

Covered when ALL of the following are met:

FDA‑approved indication: Patient has symptomatic tenosynovial giant cell tumor (pigmented villonodular synovitis)

Age requirement: Patient is ≥ 18 years of age

Surgical ineligibility: The tumor is not amenable to improvement with surgery (surgical resection would potentially cause worsening functional limitation or severe morbidity)

Romvimza (vimseltinib) is not medically necessary for any indications other than tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis. Requests for coverage for uses outside the FDA‑approved TGCT indication will be evaluated as not medically necessary and may be denied.

Any use of Romvimza other than the FDA‑approved indication for symptomatic tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis is explicitly considered not medically necessary.

Regimen	Indication	Guideline status
Romvimza (vimseltinib)
Treatment of tenosynovial giant cell tumor (TGCT) / pigmented villonodular synovitis
NCCN listed as a preferred regimen (category 1)

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for prescription benefit coverage of Romvimza. All approvals are provided for the duration noted: approve for 1 year when criteria are met.

Approve duration: 1 year when clinical criteria are met

Step Therapy

No step therapy or trial of alternate systemic agents is specified for Romvimza; there are no prior-step requirements in this policy.

Documentation Required

Required Documentation for Prior Authorization

Document required elements when submitting a prior authorization request.

Patient age (must be ≥ 18 years for FDA‑approved TGCT indication)
Diagnosis of Tenosynovial Giant Cell Tumor (TGCT) / Pigmented Villonodular Synovitis
Clinical rationale that the tumor is not amenable to improvement with surgery
Any supporting clinical information or evidence pertinent to the request

Denial Risk

Non‑covered Indications

Requests for Romvimza for any use(s) other than the FDA‑approved TGCT indication will be considered not medically necessary and are not covered unless supportive evidence and criteria are later added.

Denial Risk

Coding / Claim Denial Risk

Claims must be submitted with covered diagnosis and/or procedure codes. Claims without a covered diagnosis will be denied as not covered.

Background on Romvimza (vimseltinib)

Romvimza (vimseltinib) is a small‑molecule kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT; also called pigmented villonodular synovitis) in adults when surgical resection could potentially worsen functional limitation or cause severe morbidity. Prior authorization is recommended for prescription benefit coverage, and when criteria are met approvals are granted for 1 year. Clinical guidance notes Romvimza is listed as a preferred regimen for TGCT in NCCN soft tissue sarcoma recommendations.

Definitions

Tenosynovial giant cell tumor (TGCT)

DefinitionTenosynovial giant cell tumor (TGCT) is a neoplasm of the synovium; it is the disease indication for which Romvimza is FDA‑approved.

Alternate nameAlso known as pigmented villonodular synovitis (PVNS).

FDA‑approved populationAdults with symptomatic TGCT for which surgical resection would potentially cause worsening functional limitation or severe morbidity.

Clinical relevanceIndication specifies situations where surgery is likely to worsen function or cause severe morbidity, guiding medical therapy selection.

Policy Summary

PayerCigna

PolicyRomvimza (vimseltinib) prior authorization for tenosynovial giant cell tumor

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 19, 2025

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and document age (≥18), TGCT diagnosis, and that the tumor is not amenable to improvement with surgery; approvals are for 1 year when criteria met.

SourceLink

On This Page

OpenPayer

Romvimza (vimseltinib) prior authorization for tenosynovial giant cell tumor

Coverage Criteria for Romvimza (vimseltinib)

Preferred Regimens and Guideline Designation

Coding Guidance

Provider Actions and Prior Authorization

Line of Therapy and Salvage Use

Background on Romvimza (vimseltinib)

Definitions